A study was designed to characterize extended-spectrum-␤-lactamase (ESBL)-producing Escherichia coli isolates causing bacteremia over an 8-year period (2000 to 2007) in a large well-defined geographical region. Molecular characterization was done by using isoelectric focusing; PCR; and sequencing of the bla CTX-M -, bla TEM -, bla OXA -, bla SHV -, and plasmid-mediated quinolone resistance determinants. 
Organisms (especially Klebsiella spp. and Escherichia coli) producing extended-spectrum ␤-lactamases (ESBLs) are clinically relevant and are important causes of the failure of therapy with cephalosporins, especially when they are responsible for bloodstream-associated infections (16) . Bacteremia caused by ESBL-producing members of the family Enterobacteriaceae was associated with severe adverse outcomes, including higher rates of mortality, increased lengths of hospital stays, delays in the time to the receipt of the appropriate therapy, the discharge of a higher proportion of patients to chronic care, and significantly higher costs, compared to the outcomes for patients with bacteremia caused by non-ESBL producers (28) . An Italian study showed that inadequate initial therapy and an unidentified source of the primary infection were predictors of mortality for patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae (32) .
E. coli strains producing CTX-M ␤-lactamases have become prevalent over the last 5 years, especially in certain European and South American countries (4) . Infections caused by bacteria producing these enzymes are not limited to the hospital setting, and their potential for spread beyond the hospital environment is an important public health concern (23) . CTX-Mproducing E. coli strains isolated from hospital and community sites often exhibit coresistance to trimethoprim-sulfamethoxazole, tetracycline, gentamicin, tobramycin, and ciprofloxacin (17) . A previous study from the Calgary Health Region in Calgary, Alberta, Canada, demonstrated that CTX-M-producing E. coli is emerging as an important cause of community-onset urinary tract infections (20) . That study showed a substantial increase of CTX-M-15-producers from urines that occurred during the latter part of the study period.
Although E. coli is the most common cause of bloodstream infections in our region, with an overall annual incidence of 30.3/100,000 population recently documented, limited data about the molecular epidemiology of ESBL-producing E. coli bacteremia at the population level in large geographical areas are available (12) .
The study described here was designed to determine if the number of ESBL-producing E. coli isolates causing bacteremia increased over an 8-year period (2000 to 2007). We also characterized these isolates to determine if CTX-M-15 producers were also emerging in our region as important causes of bloodstream-associated infections.
(These results were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC.) and uidA). A detailed protocol of the MLST procedure, including allelic type and sequence type (ST) assignment methods, available at the EcMLST website (http: //www.shigatox.net/mlst), was used in this study. The DiversiLab semiautomated repetitive sequence-based PCR typing technique was also used to identify ST131, as described previously (18) .
Statistical methods. The chi-square test and Fisher's exact test were used to compare group categorical data by using the Stata (version 9.0) program (Stata Corp., College Station, TX).
RESULTS

Patients.
During the 8 years of surveillance, a total of 67 Calgary Health Region residents with incident bloodstream infections due to ESBL-producing E. coli isolates were identified; 16/67 (24%) were classified as hospital-acquired infections, 23/67 (34%) were classified as health care-associated community-onset infections, and 28/67 (42%) were classified as community-acquired infections. The mean age of the patients was 62.4 years, and 40 (60%) of the patients were males. The majority (44 [66%]) of the patients presented with the clinical syndrome of urosepsis, followed by 14 (21%) with intra-abdominal infections (acute cholecystitis (n ϭ 9) or cholangitis (n ϭ 5), and 6 (9%) presented with primary bacteremia or sepsis without a focus. The remaining three (4%) of patients presented with respiratory infections.
Bacterial isolates and susceptibilities. During the 8-year study period, 3,060 E. coli isolates (1 isolate per patient) were isolated from blood at Calgary Laboratory Services, and 67 (2%) tested positive for ESBL production ( Table 1 ). The total number of E. coli isolates recovered from blood remained stable over the 8-year period, while the number of ESBL producers increased from 1/335 (0.3%) in 2000 to 22/436 (5%) in 2007 (Table 1) . Of the 67 isolates included in this study, 44 (66%) were resistant to SXT, 31 (47%) were resistant to TZP, 47 (70%) were resistant to TOB, 40 (60%) were resistant to GEN, and 60 (90%) were resistant to CIP. No isolate with resistance to AMK and IPM was detected.
␤-Lactamases and PMQR determinants. Of the 67 ESBLproducing E. coli isolates recovered from blood, 60 (90%) were positive for bla CTX-M genes; 32 (48%) produced CTX-M-15, 25 (37%) produced CTX-M-14, 1 (2%) produced CTX-M-24, 1 (2%) produced CTX-M-2, and 1 (2%) produced CTX-M-3, while 2 (3%) produced TEM-52, and 5 (7%) produced SHV-2 ( Table 1) (Fig. 1) .
Plasmid profiles. The restriction profiles obtained with HpaI showed that plasmids isolated from clones B, BR, and C were identical (plasmid size range, 110 to 120 kb) and were related to plasmid isolated from NR strains (plasmid size range, 130 to 140 kb).
PFGE. PFGE identified four closely related groups of E. coli isolates producing ESBLs. These were designated clone A (which produced CTX-M-14 [n ϭ 10]), clone B (which produced CTX-M-14 [n ϭ 4] and CTX-M-15 [n ϭ 14], BR (i.e., related to B, which produced CTX-M-15 [n ϭ 3]), and a separate clone named C (which produced CTX-M-15 [n ϭ 5]). The group A, B, BR, and C isolates formed separate clusters with PFGE profiles that were Ͼ80% similar. The profiles of the group BR isolates exhibited Ͼ60% similarity to the profiles of the group B isolates, which suggests that group BR is related to group B. These clones were previously reported in a molecular epidemiology study (20) .
The remaining ESBL-producing isolates demonstrated the following PFGE patterns: isolates producing CTX-M-14 (n ϭ 11), CTX-M-15 (n ϭ 10), CTX-M-3 (n ϭ 1), TEM-52 (n ϭ 2), and SHV-2 (n ϭ 5) were not clonally related; i.e., they exhibited PFGE profiles that were Ͻ80% similar and did not show patterns similar to those from clones in groups A, B, BR, and C. The isolates producing CTX-M-2 and CTX-M-24 did not provide DNA bands by the PFGE method used in this study (most likely due to nondigestion).
MLST and PCR typing. MLST and repetitive sequencebased PCR typing of the CTX-M producing isolates identified PFGE clones B and BR as ST131. Overall, 21 isolates (i.e., PFGE clones B [n ϭ 18] and BR [n ϭ 3]) were identified to be clone ST131. The distribution of clone ST131 over the study period is illustrated in Fig. 2 Characteristics of MLST clone ST131. The characteristics of clone ST131 compared to those of non-ST131 ESBL-producing E. coli are shown in Table 2 . 
DISCUSSION
Two recent reports, one from Israel (1) and one from Spain (25), revealed that CTX-M-producing E. coli is emerging as an important cause of community-onset bloodstream infections. A report from Italy has shown that these organisms are also important causes of nosocomially acquired bloodstream infections (31) . The study from Tel-Aviv in Israel investigated patients with community-onset bacteremia admitted to a hospital and found that 14% of the cases were due to ESBL-producing organisms (most often E. coli producing CTX-M-2). These bacteria were multiresistant, and nursing home residency and male sex were independent risk factors (1). Rodriguez-Bano et al. reported on 43 prospectively observed cases of ESBL-producing E. coli bloodstream infections over a 4-year period in Seville, Spain; 51% were community-onset infections most often caused by CTX-M-9-and CTX-M-14-producing isolates (25) . These bacteria were also multiresistant, and the most frequent origin of infection was the urinary and the biliary tracts. In our study, bacteremia caused by ESBL-producing E. coli isolates predominantly occurred in males presenting with urosepsis or intra-abdominal infections. In addition, these organisms were multiresistant and showed high levels of resistance to CIP, GEN, TZP, and SXT. We found that 42% of the cases were community acquired, which is markedly different from the 19% incidence of community-acquired cases found in the Spanish study (25) . This could be because our study included all cases in a large well-defined geographical region. The Spanish study was performed at a single 950-bed teaching hospital (25) .
This study described the molecular epidemiology of ESBLproducing E. coli isolates recovered from blood over an 8-year period and showed that the incidence of these types of isolates increased in the Calgary Health Region during the second half of the study period (i.e. (Fig.  1) . The increase in the number of CTX-M-15 producers recovered during the second half of the study was mostly due to an increase in the incidence of PFGE clones B and BR (which were subsequently identified as MLST clone ST131) (i.e., 2 (Fig. 1) . This was associated with community outbreaks due to PFGE clone A from 2000 to 2003. Clone A accounted for 6/10 (60%) of CTX-M-14-producing isolates in the first half of the study, whereas it accounted for 2/15 (13%) of CTX-M-14-producing isolates from 2004 to 2007. This clone had previously been described to be causing outbreaks of community-acquired urinary tract infections among older females in 2000 and 2001 (21) .
Multidrug-resistant CTX-M-15-producing E. coli is emerging worldwide as an important pathogen causing communityonset and hospital-acquired infections (26) . An identical clone named ST131 has been identified by using MLST among CTX-M-15-producing E. coli isolates recovered from 2000 to 2006 from several countries, including Spain, France, Canada, Portugal, Switzerland, Lebanon, India, Kuwait, and South Korea (6, 15) . This clone belongs to highly virulent phylogenetic group B2 and has often been found to harbor multidrug resistance plasmids of the IncFII group. Clone ST131 producing CTX-M-15 has also recently been described in the United Kingdom (10), Italy (3), Turkey (33), Croatia (14) , Japan (29) , and the United States (9) . E. coli isolates that belong to clone ST131 but that do not produce CTX-M ␤-lactamases have been isolated from the stools of healthy volunteers in Paris, France (13) . A previous study from the Calgary Health Region demonstrated that travel to the Indian subcontinent, Africa, and the Middle East was associated with a high risk of urinary tract infection (including urosepsis) caused by an ESBL-producing E. coli in returning travelers (11) , and this was mostly due to clone ST131 isolates producing CTX-M-15 (19) .
This study has shown that clone ST131 isolates coproducing CTX-M-15, OXA-1, and TEM-1 first appeared in 2003 and are emerging as important causes of bloodstream infections due to ). An interesting finding from our study was the identification of CTX-M-14-producing E. coli isolates as clone ST131. To our knowledge, this is the first study to describe the presence of CTX-M-14 in E. coli ST131. Clone ST131 producing CTX-M-14 did not produce OXA-1 or TEM-1 (as clone ST131 isolates producing CTX-M-15 do). The features of clone ST131 isolates compared to those of non-ST131 ESBL-producing E. coli isolates are summarized in Table 2 . Clone ST131 was more likely to be resistant to GEN, TOB, CIP, and TZP; more likely to produce the aminoglycoside-modifying enzyme aac(6Ј)-Ib-cr; and more likely to cause community-acquired infections and urosepsis. However, clone ST131 was less likely to cause hospital-acquired and intraabdominal types of infections.
In conclusion, our study illustrates that multidrug-resistant E. coli clone ST131 coproducing CTX-M-15, OXA-1, TEM-1, and aac(6Ј)-Ib-cr has emerged as an important cause of community-onset bacteremia. We suspect that this ESBL-producing E. coli isolate was most likely introduced into our region via foreign travel to the Indian subcontinent, Africa, and the Middle East. This is the first study to identify CTX-M-14 in E. coli clone ST131. There is a serious need to monitor the spread of this multidrug-resistant clone throughout the world. Empirical antibiotic coverage for these resistant organisms should be considered in patients in the community presenting with sepsis involving the urinary and biliary tracts, especially in areas with a high prevalence of ESBL-producing E. coli isolates.
